Table 1.
Demographics and clinical features by antibody status
| ANA* (N=2085) | Anti-Scl-70 (N=854) | Anti-RNA Pol 3 (N=86) | ACA (N=775) | Anti-U1 RNP (N=120) | Anti-U3 RNP (N=39) | |
|---|---|---|---|---|---|---|
| Tested positive/tests performed (%) | 2085/2179 (95.7) | 854/1888 (45.2) | 86/867 (9.9) | 775/1778 (43.6) | 120/1243 (9.7) | 39/799 (4.9) |
| Female, n/N (%) | 1719/2085 (82.4) | 676/854 (79.2) | 70/86 (81.4) | 677/775 (87.4) | 91/120 (75.8) | 31/39 (29.5) |
| dcSSc, n/N (%) (95% CI) | 776/2070 (37.5) (35.4 to 39.6) | 557/848 (65.7) (62.4 to 68.9) | 37/85 (43.5) (32.8 to 54.7) | 91/770 (11.8) (9.6 to 14.3) | 34/119 (28.6) (20.7 to 37.6) | 10/38 (26.3) (13.4 to 43.1) |
| lcSSc, n/N (%) (95% CI) | 1071/2070 (51.7) (49.6 to 53.9) | 249/848 (29.4) (26.3 to 32.6) | 28/85 (32.9) (23.1 to 44.0) | 638/770 (82.9) (80.0 to 85.5) | 38/119 (31.9) (23.7 to 41.1) | 15/38 (39.5) (24.0 to 56.6) |
| Overlap SSc/mCTD, n/N (%) (95% CI) | 149/2070 (7.2) (6.1 to 8.6) | 17/848 (2.0) (1.2 to 3.2) | 14/85 (16.5) (9.3 to 26.1) | 23/770 (3.0) (1.9 to 4.5) | 40/119 (33.6) (25.2 to 42.8) | 12/38 (31.6) (17.5 to 48.7) |
| Age at enrolment, years, mean (95% CI) | 54.4 (53.8 to 55.0) | 52.4 (51.4 to 53.3) | 51.3 (48.4 to 54.2) | 58.1 (57.2 to 59.1) | 49.9 (47.4 to 52.5) | 48.5 (44.0 to 53.0) |
| Age at RP onset, years, mean (95% CI) | 39.7 (39.0 to 40.5) | 38.5 (37.5 to 39.6) | 37.6 (34.7 to 40.6) | 41.1 (39.9 to 42.3) | 35.7 (32.9 to 38.6) | 33.7 (28.5 to 38.9) |
| Age at first digital ulcer, years, mean (95% CI) | 46.6 (45.9 to 47.4) | 44.7 (43.6 to 45.7) | 44.1 (41.1 to 47.2) | 50.1 (48.9 to 51.3) | 42.6 (39.6 to 45.5) | 38.8 (33.6 to 44.0) |
| Time from onset of RP to first digital ulcer, years, mean (95% CI) | 6.6 (6.2 to 7.0) | 6.0 (5.4 to 6.6) | 6.1 (4.4 to 7.8) | 8.1 (7.3 to 9.0) | 6.5 (4.9 to 8.0) | 6.9 (3.5 to 10.4) |
| Time from first non-RP to first digital ulcer manifestation, years, mean (95% CI) | 3.6 (3.3 to 3.9) | 3.2 (2.9 to 3.6) | 3.6 (2.5 to 4.8) | 3.9 (3.4 to 4.5) | 3.8 (2.7 to 4.9) | 4.6 (1.9 to 7.4) |
The denominator N varies according to the number of available observations.
*
Antibody subsets are not mutually exclusive: one patient can have several antibodies and therefore contribute to several groups.
ACA, anticentromere antibodies; ANA, antinuclear antibodies; anti-Scl-70, anti-scleroderma-70 antibodies; anti-RNA Pol 3, anti-RNA polymerase 3; anti-U1 RNP, anti-U1 ribonucleoprotein; anti-U3 RNP, anti-U3 ribonucleoprotein; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; mCTD, mixed connective tissue disease; RP, Raynaud's phenomenon; SSc, systemic sclerosis.